Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
George J. Netto & Jonathan I. Epstein. (2010) Theranostic and prognostic biomarkers: genomic applications in urological malignancies. Pathology 42:4, pages 384-394.
Read now
Read now
Articles from other publishers (36)
Kornkamon Lertsuwan, Leila H. Choe, Irene R. Marwa, Kelvin Lee & Robert A. Sikes. (2017) Identification of Fibulin‐1 as a Human Bone Marrow Stromal (HS‐5) Cell‐Derived Factor That Induces Human Prostate Cancer Cell Death. The Prostate 77:7, pages 729-742.
Crossref
Crossref
Godfrey Grech, Xianquan Zhan, Byong Chul Yoo, Rostyslav Bubnov, Suzanne Hagan, Romano Danesi, Giorgio Vittadini & Dominic M Desiderio. (2015) EPMA position paper in cancer: current overview and future perspectives. EPMA Journal 6:1.
Crossref
Crossref
YA-PING LIU, GUO-FU HU & YUN-XIA WU. (2015) Neamine is preferential as an anti-prostate cancer reagent by inhibiting cell proliferation and angiogenesis, with lower toxicity than cis-platinum. Oncology Letters 10:1, pages 137-142.
Crossref
Crossref
Emma E. Oldridge, Davide Pellacani, Anne T. Collins & Norman J. Maitland. (2012) Prostate cancer stem cells: Are they androgen-responsive?. Molecular and Cellular Endocrinology 360:1-2, pages 14-24.
Crossref
Crossref
Adeboye O. Osunkoya. (2012) Update on prostate pathology. Pathology 44:5, pages 391-406.
Crossref
Crossref
George J. Netto & Liang Cheng. (2012) Emerging Critical Role of Molecular Testing in Diagnostic Genitourinary Pathology. Archives of Pathology & Laboratory Medicine 136:4, pages 372-390.
Crossref
Crossref
George J. Netto. (2011) Molecular Diagnostics in Urologic Malignancies: A Work in Progress. Archives of Pathology & Laboratory Medicine 135:5, pages 610-621.
Crossref
Crossref
O J C Hellwinkel, L E Asong, J-P Rogmann, H Sültmann, C Wagner, T Schlomm & C Eichelberg. (2010) Transcription alterations of members of the ubiquitin–proteasome network in prostate carcinoma. Prostate Cancer and Prostatic Diseases 14:1, pages 38-45.
Crossref
Crossref
George J. Netto & Jonathan I. Epstein. 2011. Diagnostic Immunohistochemistry. Diagnostic Immunohistochemistry
593
661
.
Cigdem Erten, Burcak Karaca, Yuksel Kucukzeybek, Gurbuz Gorumlu, Ercument Cengiz, Mustafa K. Gul, Harika Atmaca, Selim Uzunoglu, Bulent Karabulut, Ulus A. Sanli & Ruchan Uslu. (2009) Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide. BJU International 104:1, pages 107-114.
Crossref
Crossref
Takuya Fujita, Koji Teramoto, Yoshitomo Ozaki, Jun Hanaoka, Noriaki Tezuka, Yasushi Itoh, Tohru Asai, Shozo Fujino, Keiichi Kontani & Kazumasa Ogasawara. (2009) Inhibition of Transforming Growth Factor-β–Mediated Immunosuppression in Tumor-Draining Lymph Nodes Augments Antitumor Responses by Various Immunologic Cell Types. Cancer Research 69:12, pages 5142-5150.
Crossref
Crossref
Julie Kanter, Samina Y. Khan, Marguerite Kelher, Lia Gore & Christopher C. Silliman. (2008) Oncogenic and Angiogenic Growth Factors Accumulate during Routine Storage of Apheresis Platelet Concentrates. Clinical Cancer Research 14:12, pages 3942-3947.
Crossref
Crossref
Alan A. Aitchison, Abhi Veerakumarasivam, Maria Vias, Rajeev Kumar, Freddie C. Hamdy, David E. Neal & Ian G. Mills. (2008) Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. The Prostate 68:6, pages 661-674.
Crossref
Crossref
Chung Lee, Ali Shah, Victoria C. Liu, Irwin I. Park, Larry Y. Wong, Xuemei Huang, Lijun Huang, Vivian W. Zhou, Terry Medler, Shilajit D. Kundu, Qiang Zhang & Norm D. Smith. 2008. Transforming Growth Factor-β in Cancer Therapy, Volume II. Transforming Growth Factor-β in Cancer Therapy, Volume II
443
461
.
Sonia B. JakowlewTetsu Hayashida, Vandana Gupta, Sam Thiagalingam & Shyamala Maheswaran. 2008. Transforming Growth Factor-β in Cancer Therapy, Volume I. Transforming Growth Factor-β in Cancer Therapy, Volume I
355
372
.
Georgios Pampalakis & Georgia Sotiropoulou. (2007) Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1776:1, pages 22-31.
Crossref
Crossref
Chung Lee, Ali Shah, Victoria Liu, Irwin Park, Larry Wong, Xuemei Huang, Lijun Huang, Tim Fermin, Tom Jang, Som Kundu, Vivian Zhou, Qiang Zhang & Norm Smith. 2007. Prostate Cancer. Prostate Cancer
165
174
.
Trinh T. Tran, Dorry L. Segev, Vandana Gupta, Hirofumi Kawakubo, Giminna Yeo, Patricia K. Donahoe & Shyamala Maheswaran. (2006) Mullerian Inhibiting Substance Regulates Androgen-Induced Gene Expression and Growth in Prostate Cancer Cells through a Nuclear Factor-κB-Dependent Smad-Independent Mechanism. Molecular Endocrinology 20:10, pages 2382-2391.
Crossref
Crossref
Qiang Zhang, Ximing J. Yang, Shilajit D. Kundu, Michael Pins, Borko Javonovic, Robert Meyer, Seong-Jin Kim, Norman M. Greenberg, Timothy Kuzel, Richard Meagher, Yinglu Guo & Chung Lee. (2006) Blockade of transforming growth factor-β signaling in tumor-reactive CD8+ T cells activates the antitumor immune response cycle. Molecular Cancer Therapeutics 5:7, pages 1733-1743.
Crossref
Crossref
Qiang Zhang, Thomas L. Jang, Ximing Yang, Irwin Park, Robert E. Meyer, Shilajit Kundu, Michael Pins, Borko Javonovic, Timothy Kuzel, Seong-Jin Kim, Luk Van Parijs, Norm Smith, Larry Wong, Norman M. Greenberg, Yinglu Guo & Chung Lee. (2006) Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells. The Prostate 66:3, pages 235-247.
Crossref
Crossref
Hong Zhao, Hiroaki Shiina, Kirsten L. Greene, Long‐Cheng Li, Yuichiro Tanaka, Hirofumi Kishi, Mikio Igawa, Christopher J. Kane, Peter Carroll & Rajvir Dahiya. (2005)
CpG methylation at promoter site −140 inactivates
TGFβ2
receptor gene in prostate cancer
. Cancer 104:1, pages 44-52.
Crossref
Crossref
B K Suarez, P Pal, C H Jin, R Kaushal, G Sun, L Jin, B Pasche, R Deka & W J Catalona. (2004) TGFBR1*6A is not associated with prostate cancer in men of European ancestry. Prostate Cancer and Prostatic Diseases 8:1, pages 50-53.
Crossref
Crossref
Gerold Untergasser, Roland Gander, Claudia Lilg, Günter Lepperdinger, Eugen Plas & Peter Berger. (2005) Profiling molecular targets of TGF-β1 in prostate fibroblast-to-myofibroblast transdifferentiation. Mechanisms of Ageing and Development 126:1, pages 59-69.
Crossref
Crossref
Yong Wei & Jessie L.-S. Au. 2005. Integration/Interaction of Oncologic Growth. Integration/Interaction of Oncologic Growth
285
321
.
Tomasz M. Beer, Anne Myrthue, Mark Garzotto, Michael F. O'Hara, Raymond Chin, Bruce A. Lowe, Michelle A. Montalto, Christopher L. Corless & W. David Henner. (2004) Randomized Study of High-Dose Pulse Calcitriol or Placebo prior to Radical Prostatectomy. Cancer Epidemiology, Biomarkers & Prevention 13:12, pages 2225-2232.
Crossref
Crossref
O. Sinnreich, J. Kratzsch, A. Reichenbach, C. Gläser, K. Huse & G. Birkenmeier. (2004) Plasma levels of transforming growth factor‐1β and α2‐macroglobulin before and after radical prostatectomy: association to clinicopathological parameters. The Prostate 61:3, pages 201-208.
Crossref
Crossref
Carol J. Swallow, Emily A. Partridge, Jennifer C. Macmillan, Tania Tajirian, Gianni M. DiGuglielmo, Kazy Hay, Melanie Szweras, Willi Jahnen-Dechent, Jeff L. Wrana, Mark Redston, Steven Gallinger & James W. Dennis. (2004)
α2HS-glycoprotein, an Antagonist of Transforming Growth Factor β
In vivo
, Inhibits Intestinal Tumor Progression
. Cancer Research 64:18, pages 6402-6409.
Crossref
Crossref
Yansong Bian, Virginia Kaklamani, Jennifer Reich & Boris Pasche. 2004. Signal Transduction in Cancer. Signal Transduction in Cancer
73
94
.
G. Untergasser, R. Gander, H. Rumpold, E. Heinrich, E. Plas & P. Berger. (2003) TGF-β cytokines increase senescence-associated beta-galactosidase activity in human prostate basal cells by supporting differentiation processes, but not cellular senescence. Experimental Gerontology 38:10, pages 1179-1188.
Crossref
Crossref
Jack H. Mydlo & Paul Crispen. 2003. Prostate Cancer. Prostate Cancer
63
68
.
Michael J. Wilson, Robert G. Sellers, Carol Wiehr, Ori Melamud, Duanqing Pei & Donna M. Peehl. (2002) Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells. Journal of Cellular Physiology 191:2, pages 208-216.
Crossref
Crossref
Jeffrey S. Ross, Christine E. Sheehan, Eric M. Dolen & Bhaskar V. S. Kallakury. (2002) Morphologic and Molecular Prognostic Markers in Prostate Cancer. Advances in Anatomic Pathology 9:2, pages 115-128.
Crossref
Crossref
Dorry L. Segev, Yasunori Hoshiya, Makiko Hoshiya, Trinh T. Tran, Jennifer L. Carey, Antonia E. Stephen, David T. MacLaughlin, Patricia K. Donahoe & Shyamala Maheswaran. (2002)
Mullerian-inhibiting substance regulates NF–κB signaling in the prostate
in vitro
and
in vivo
. Proceedings of the National Academy of Sciences 99:1, pages 239-244.
Crossref
Crossref
Ursula Elsässer-Beile, Wolfgang Schultze-Seemann & Ulrich Wetterauer. 2002. Molekularmedizinische Grundlagen von nicht-hereditären Tumorerkrankungen. Molekularmedizinische Grundlagen von nicht-hereditären Tumorerkrankungen
329
361
.
Maria Mercader, Barbara K. Bodner, Micheal T. Moser, Pamela S. Kwon, Eugene S. Y. Park, Ryan G. Manecke, Thomas M. Ellis, Eva M. Wojcik, Damu Yang, Robert C. Flanigan, W. Bedford Waters, W. Martin Kast & Eugene D. Kwon. (2001) T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proceedings of the National Academy of Sciences 98:25, pages 14565-14570.
Crossref
Crossref
Boris Pasche. (2001) Role of transforming growth factor beta in cancer. Journal of Cellular Physiology 186:2, pages 153-168.
Crossref
Crossref